TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'
August 2, 2023 7:09 AM EDTGoldman Sachs analyst Corinne Jenkins upgraded TG Therapeutics (NASDAQ: TGTX) from Sell to Neutral with a price target of $12.00 (from $16.00).
The analyst comments "We upgrade TGTX to Neutral from Sell and lower our 12-month price target to $12 ($16 prior). TGTX shares closed -50% (vs. XBI -1.2%) following 2Q23 EPS, which included revenue of $16.0M, well... More
TG Therapeutics (TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
August 1, 2023 7:28 AM EDTTG Therapeutics (NASDAQ: TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
... MoreTG Therapeutics (TGTX) Misses Q2 EPS by 10c
August 1, 2023 7:22 AM EDTTG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $16.3 million.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More